A Review on Prescription Opioid Abuse - Are Abuse Deterrent Formulations a Solution
Keywords:
Prescription Opioid Abuse, Abuse Deterrent Formulations a SolutionAbstract
Non-medical prescription opioid drug use is a growing problem in India. The development of abuse-deterrent formulations (ADFs) of prescription opioid analgesics is a novel strategy toward reducing abuse and diversion of these medications. However, drug abuse still remains a problem as the addict may switch over to other accessible non abuse-deterrent opioids. Moreover opioid ADFs may themselves be abused via the intended route of administration by increasing the dose or dosing frequency. This review stresses upon the need to further elucidate the risk and benefit of long term opioid therapy and ADFs in the management of chronic non-malignant pain.
Downloads
References
Daubresse M, Chang HY, Yu Y, Viswanathan S, Shah ND, Stafford RS, et al. Ambulatory diagnosis and treatment of nonmalignant pain in the United States, 2000-2010. Med Care. 2013; 51(10):870-8.
International Association for the Study of Pain. Classification of chronic pain. Descriptions of chronic pain syndromes and definitions of pain terms. Prepared by the International Association for the Study of Pain, Subcommittee on Taxonomy. Pain Suppl 1986; 3:S1–226.
Moorman-Li R, Motycka CA, Inge LD, Congdon JM, Hobson S, Pokropski B. A Review of AbuseDeterrent Opioids For Chronic Nonmalignant Pain. Continuing Education Credit for Physicians and Pharmacists. 2012; 37(7):412-8.
Smith SM, Dart RC, Katz NP, Paillard F, Adams EH, Comer SD, et al. Classification and definition of misuse, abuse, and related events in clinical trials: A C T T I O N s y s t e m a t i c r e v i e w a n d recommendations. Pain. 2013; 154(11):2287-96.
Nattala P, Murthy P, Kandavel T, Cottler LB. NonMedical Use of Prescription Drugs in Bangalore, India. Ind J Public Health. 2015;59(2):87-94.
Hale ME, Moe D, Bond M, Gasior M, Malamut R. Abuse-deterrent formulations of prescription opioid analgesics in the management of chronic noncancer pain. Pain Manag. 2016;6(5):497-508.
Fishbain DA, Cole B, Lewis J, Rosomoff HL, Rosomoff RS. What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review. Pain Med. 2008;9(4):444-59.
Ling W, Mooney L, Hillhouse M. Prescription opioid abuse, pain and addiction: Clinical issues and implications. Drug Alcohol Rev. 2011; 30(3):300-5.
Becker WC, Fiellin DA. Abuse-Deterrent Opioid Formulations — Putting the Potential Benefits into Perspective. N Engl J Med. 2017;376(22):2103-5.
Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2 0 1 6 . R e c o m m e n d a t i o n s a n d R e p o r t s . 2016;65(1):1-49.
Noble M, Treadwell JR, Tregear SJ, Coates VH, Wiffen PJ, Akafomo C, et al. Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev. 2010;1:CD006605.
Chou R, Turner JA, Devine EB, Hansen RN, Sullivan SD, Blazina I, et al. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med. 2015; 162:276-86.
Coplan PM, Kale H, Sandstrom L, Landau C, Chilcoat HD. Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abusedeterrent characteristics. Pharmacoepidemiol Drug Saf. 2013; 22:1274-82. [132]
Cicero TJ, Ellis MS. Abuse-deterrent formulations and the prescription opioid abuse epidemic in the United States: lessons learned from OxyContin. JAMA Psychiat. 2015; 72:424-30.
Larochelle MR, Zhang F, Ross-Degnan D, Wharam JF. Rates of opioid dispensing and overdose after introduction of abuse-deterrent extended-release oxycodone and withdrawal of propoxyphene. JAMA Intern Med. 2015;175:978–87.
Weisberg DF, Gordon KS, Barry DT, Becker WC, Crystal S, Edelman EJ, et al. Long-term prescription of opioids and/or benzodiazepines and mortality among HIVinfected and uninfected patients. J Acquir Immune Defic Syndr. 2015; 69:223-33.
Simon K, Worthy SL, Barnes MC, Tarbell B. Abusedeterrent formulations: transitioning the pharmaceutical market to improve public health and safety. Ther Adv Drug Saf. 2015; 6:67–79. Institute of Medicine. Relieving pain in America: a blueprint for transforming prevention, care, education, and research. Washington, DC: The National Academies Press; 2011.
